Quark Pharmaceuticals Overview
- Founded
-
1994

- Status
-
Acquired/Merged
- Employees
-
54

- Latest Deal Type
-
M&A
- Financing Rounds
-
14
- Investments
-
1
Quark Pharmaceuticals General Information
Description
Developer of therapeutic Ribonucleic acid interference (RNAi) drugs based in Newark, California. The company offers services catering to the discovery and development of novel small interfering RNA (siRNA) therapeutics for renal protection in cardio-renal disease and neuroprotection in ophthalmology.
Contact Information
Website
www.quarkpharma.com
Formerly Known As
Quark Biotech
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 7999 Gateway Boulevard
- Suite 310
- Newark, CA 94560
- United States
Quark Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Quark Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic Ribonucleic acid interference (RNAi) drugs based in Newark, California. The company offers serv
Drug Discovery
Newark, CA
54
As of 2016
00000
000000&0
Quark Pharmaceuticals Competitors (46)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
aTyr Pharma | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
0000000 | Venture Capital-Backed | Toronto, Canada | 00 | 000.00 | 00000 | 000.00 |
000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 000.00 | 00000000 | 000.00 |
000000000 | Formerly VC-backed | Vancouver, Canada | 000 | 00000 | 00000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000000 | 00000 |
Quark Pharmaceuticals Patents
Quark Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201413538-D0 | Ophthalmic compositions and uses thereof | Ceased | 30-Jul-2014 | 0000000000 | |
JP-2020128383-A | Methods and compositions for preventing ischemia-reperfusion injury in organs | Pending | 29-May-2014 | 000000000 | |
EP-3444349-B1 | Methods and compositions for preventing ischemia reperfusion injury in organs | Active | 29-May-2014 | 000000000 | |
JP-2017521374-A | Methods and compositions for preventing ischemia-reperfusion injury of organs | Withdrawn | 29-May-2014 | 00000000000 | |
ES-2862185-T3 | Methods and compositions to avoid ischemia-reperfusion injury to organs | Active | 29-May-2014 | C12N15/1135 |
Quark Pharmaceuticals Signals
Quark Pharmaceuticals Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Quark Pharmaceuticals Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 01-Sep-2012 | 00000 0000 | Pharmaceuticals |